Results 91 to 100 of about 274,125 (232)

Role of Lactobacillus crispatus in vaginal infections: insights from metagenomics and metabolomics studies [PDF]

open access: yes, 2019
Objective: Lactobacillus spp. constitute the most prevalent bacterial microorganism in the vaginal milleu. Several probiotic mechanisms have been associated with Lactobacillus, but the most relevant one is lactate production – resulting in a low pH value,
Donder, G.   +5 more
core  

Current treatment options for postmenopausal vaginal atrophy [PDF]

open access: yes, 2019
Vulvovaginal atrophy (VVA) is a silent epidemic that affects up to 50%-60% of postmenopausal women who are suffering in silence from this condition. Hormonal changes, especially hypoestrogenism inherent in menopause, are characterized by a variety of ...
Castelo-Branco Flores, Camil   +1 more
core   +1 more source

Vulvovaginal atrophy in the CRETA study: the healthcare professionals’ perception

open access: yesGynecological Endocrinology, 2023
The objective is to assess the perception of gynecologists regarding patients' adherence to vulvovaginal atrophy (VVA) treatments, to evaluate the gynecologists' opinions on what their patients think about treatment adherence, and to compare the gynecologists' opinions with the patients' own perceptions within the CRETA study.Spanish gynecologists who ...
María J. Cancelo   +8 more
openaire   +3 more sources

Evidence‐ and consensus‐based guideline on lichen sclerosus

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 4, Page 566-584, April 2026.
Summary The German‐language, consensus‐ and evidence‐based S3 guideline on lichen sclerosus (LS) was developed based on the European “EuroGuiDerm Guideline on lichen sclerosus” under the leadership of the German Dermatological Society (DDG) and the German Society for Gynecology and Obstetrics (DGGG).
Gudula Kirtschig   +25 more
wiley   +1 more source

Modern approach to the management of genitourinary syndrome in women with gynecological malignancies

open access: yesRadiology and Oncology, 2023
The term genitourinary syndrome of menopause was first used in 2014 by the North American Menopause Society and the International Society for the Study of Women's Sexual Health to describe conditions previously known as atrophic vaginitis, urogenital ...
Kovacevic Nina   +3 more
doaj   +1 more source

Postmenopausal Vaginal Microbiome and Microbiota

open access: yesFrontiers in Reproductive Health, 2022
The ovulatory cycle has a significant influence on the microbial composition, according to the action of estrogen and progesterone on the stratified squamous epithelium, due to an increase in epithelial thickness, glycogen deposition, and influence on ...
Nayara Santos de Oliveira   +6 more
doaj   +1 more source

Efficacy of Vaginal Laser Treatment for Symptomatic Relief of Vulvovaginal Atrophy in Postmenopausal Women [PDF]

open access: yes, 2021
Introduction: As women age and go through menopause, the decrease in estrogen that occurs with this process causes many changes in the body, one being atrophy of the vaginal skin, The thinning and drying of the vaginal canal as well as the external ...
Parker, Kathleen
core   +1 more source

Elasticity Improvement and Water Loss Prevention in Vulvar Skin by Topical Nonhormonal Moisturizer

open access: yesJEADV Clinical Practice, Volume 5, Issue 1, Page 117-123, March 2026.
Effect of topical non‐hormonal moisturizer on the vulva in postmenopausal women. Moisturizer is completely absorbed. Water loss from vulva is reduced by 51% compared to baseline measurements. Elasticity is improved by 21% compared to baseline measurements.
Hans Christian Wulf   +2 more
wiley   +1 more source

Using advanced analytics to help identify women who are more likely to have a severe subjective experience of vulvovaginal atrophy: a modeling study

open access: yesGynecological Endocrinology, 2023
Objective To develop a model to identify women likely to be severely impacted by vulvovaginal atrophy (VVA), based on their experience of symptoms and non-clinical factors.Methods Multivariate statistics and machine-learning algorithms were used to ...
Rossella E. Nappi   +6 more
doaj   +1 more source

Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon‐Like Peptide 1 Agonist: A Case Report

open access: yesRespirology Case Reports, Volume 14, Issue 3, March 2026.
Cystic fibrosis (CF) modulator therapies can lead to rapid and excessive weight gain. Obesity in CF can lead to undesirable metabolic complications including type 2 diabetes. Therefore, glucagon‐like peptide 1 (GLP‐1) agonists which can facilitate weight loss and improve metabolic profiles are increasingly prescribed to people with CF.
Shanal Kumar   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy